Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 2

Status

Unknown 1Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 92Lymphoid 2

Conditions

Lymphoma 340Lymphoma, Non-Hodgkin 295Precursor Cell Lymphoblastic Leukemia-Lymphoma 249Leukemia, Lymphocytic, Chronic, B-Cell 235Lymphoma, Large B-Cell, Diffuse 217Leukemia 186Lymphoma, Follicular 183Lymphoma, Mantle-Cell 167Recurrence 142Hodgkin Disease 141Lymphoma, B-Cell 139Leukemia, Myeloid, Acute 133Burkitt Lymphoma 120Lymphoma, B-Cell, Marginal Zone 94Multiple Myeloma 86Myelodysplastic Syndromes 83Waldenstrom Macroglobulinemia 62Lymphoma, T-Cell, Peripheral 57Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 52Neoplasms 52Lymphoma, T-Cell, Cutaneous 52Hematologic Neoplasms 49Lymphoma, Large-Cell, Anaplastic 43Lymphoma, T-Cell 41Lymphoma, Large-Cell, Immunoblastic 41Leukemia, Myelogenous, Chronic, BCR-ABL Positive 40Mycosis Fungoides 38Leukemia, B-Cell 34Sezary Syndrome 30Myeloproliferative Disorders 29

Interventions

urelumab 1apatinib 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Advanced Solid Tumors × Lymphoid × Clear all
NCT02253992 2020-10-05

An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma

Bristol-Myers Squibb

Phase 1/2 Terminated
232 enrolled 17 charts
LymphoidOther solid neoplasm

Advanced Solid Tumors

NCT02844881 2016-08-11

Study of Apatinib and MASCT in Patients With Advanced Solid Tumors

The First People's Hospital of Lianyungang

Phase 1/2 Unknown
60 enrolled
LymphoidOther solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡